evaluation of the effects of Ascorbic acid on attenuation of the statin induced myopathy

Clinical evaluation of the effects of Ascorbic acid on attenuation of the statin induced myopathy: a randomized double blinded placebo-controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191106045356N2

Enrollment

Registered

2021-04-18

Start date

2021-05-20

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopathy. Drug-induced myopathy

Interventions

Intervention 1: Includes 20 patients who are randomly selected based on the RND() function of Excel software. Patients receive two 500 mg of vitamin C capsules daily made by an Iranian pharmaceutical

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: People between 80-30 years old Patients undergoing exercise for cardiac rehabilitation Daily intake of 40 mg of atorvastatin Maximum weight 80 kg Non-pregnancy of women The patient should not have severe peptic ulcer

Exclusion criteria

Exclusion criteria: Vitamin C intolerance Do not take medication for more than two consecutive days Do not take atorvastatin for more than two consecutive days The patient becomes pregnant

Design outcomes

Primary

Measure	Time frame
Creatine kinase, aldolase and lactate dehydrogenase levels. Timepoint: Evaluation of patient tests on days 1 and 14 of the intervention. Method of measurement: Patient blood test and measurement of creatine kinase, aldolase and lactate dehydrogenase using relevant kits.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohsen Zabihi

Yazd University of Medical Sciences

mzabihi100@gmail.com+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026